Christopher Blaum

Christopher Blaum

Auto-generated profile, based on publicly available information

Christopher Blaum

Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf , Hamburg , Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
NANatalie Arnold
Natalie Arnold
CBChristopher Blaum
Christopher Blaum
AGAlina Goßling
Alina Goßling
FBFabian J Brunner
Fabian J Brunner
BBBenjamin Bay
Benjamin Bay
CWChristoph Waldeyer
Christoph Waldeyer
Recent investigations have suggested an interdependence of lipoprotein(a) [Lp(a)]-related risk for cardiovascular disease with background inflammatory burden. The aim the present analysis was to investigate whether high-sensitive C-reactive protein (hsCRP) modulates the association between Lp(a) and coronary heart disease (CHD) in the general population. Data from 71 678 participants from 8 European prospective population-based cohort studies were used (65 661 without/6017 with established CHD at baseline; median follow-up 9.8/13.8 years, respectively). Fine and Gray competing risk-adjusted models were calculated according to accompanying hsCRP concentration (<2 and ≥2 mg/L). Among CHD-free individuals, increased Lp(a) levels were associated with incident CHD irrespective of hsCRP concentration: fully adjusted sub-distribution hazard ratios [sHRs (95% confidence interval)] for the highest vs. lowest fifth of Lp(a) distribution were 1.45 (1.23–1.72) and 1.48 (1.23–1.78) for a hsCRP group of <2 and ≥2 mg/L, respectively, with no interaction found between these two biomarkers on CHD risk (Pinteraction = 0.82). In those with established CHD, similar associations were seen only among individuals with hsCRP ≥ 2 mg/L [1.34 (1.03–1.76)], whereas among participants with a hsCRP concentration <2 mg/L, there was no clear association between Lp(a) and future CHD events [1.29 (0.98–1.71)] (highest vs. lowest fifth, fully adjusted models; Pinteraction = 0.024). While among CHD-free individuals Lp(a) was significantly associated with incident CHD regardless of hsCRP, in participants with CHD at baseline, Lp(a) was related to recurrent CHD events only in those with residual inflammatory risk. These findings might guide adequate selection of high-risk patients for forthcoming Lp(a)-targeting compounds. C-reactive protein as a possible modifier of lipoprotein(a)-related risk for coronary heart disease in Europe. CHD, coronary heart disease; CI, confidence interval; Lp(a), lipoprotein(a); FU, follow-up; F, fifth; hsCRP, high-sensitive C-reactive protein; sHR, sub-distribution hazard ratio.

19 July 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
BBBenjamin Bay
Benjamin Bay
AGAlina Goßling
Alina Goßling
CBChristopher M. Blaum
Christopher M. Blaum
FKFriederike Kroeger
Friederike Kroeger
LKLuise Koppe
Luise Koppe
FBFabian J. Brunner
Fabian J. Brunner
Background: The association between high‐sensitivity troponin T (hsTnT) and high‐sensitivity troponin I (hsTnI) and outcome when adjusted for confounders including the angiographical severity of coronary artery disease (CAD) remains largely unknown. We therefore aimed to explore whether hsTnT and hsTnI blood levels increase with CAD severity and add independent predictive information for future major adverse cardiovascular events and all‐cause mortality in stable patients. Methods and Results: Patients from the INTERCATH cohort with available coronary angiography and hsTnT and hsTnI concentrations were included. Troponin concentrations were quantified via hsTnT (Roche Elecsys) and hsTnI (Abbott ARCHITECT STAT). To investigate the association of hsTnT and hsTnI with outcome, a multivariable analysis adjusting for classical cardiovascular risk factors, low‐density lipoprotein cholesterol, estimated glomerular filtration rate, hs‐CRP (high‐sensitivity C‐reactive protein), NT‐proBNP (N‐terminal pro–brain natriuretic peptide), and Gensini score was carried out. Of 1829 patients, 27.9% were women, and the mean age was 68.6±10.9 years. Troponin blood concentrations were higher in patients with diagnosed CAD compared with those without. Using a linear regression model current smoking, arterial hypertension, estimated glomerular filtration rate, hs‐CRP, NT‐proBNP, and CAD severity as graded by the Gensini and SYNTAX scores were associated with high‐sensitivity troponin levels. Patients were followed for 4.4 years (25th and 75th percentiles: 4.3, 4.4). After multivariable adjustment, all‐cause mortality was predicted by hsTnT (hazard ratio [HR], 1.7 [95% CI, 1.5–2.2], P <0.001) as well as hsTnI (HR, 1.5 [95% CI, 1.2–1.8], P <0.001). However, only hsTnI (HR, 1.2 [95% CI, 1.0–1.4], P =0.032) remained as an independent predictor of major adverse cardiovascular events after adjusting for most possible confounders, including CAD severity (hsTnT: HR, 1.0 [95% CI, 0.9–1.2], P =0.95). Conclusions: After adjusting for classical cardiovascular risk factors, low‐density lipoprotein cholesterol, estimated glomerular filtration rate, hs‐CRP, NT‐proBNP, and CAD severity, hsTnT and hsTnI were independently associated with all‐cause mortality, but only hsTnI was associated with major adverse cardiovascular events in stable patients undergoing coronary angiography. Registration: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT04936438.

1 January 2024 in EuroIntervention
Verified
Journal Article
Closed access
BBBenjamin Bay
Benjamin Bay
LKLuisa M. Kiwus
Luisa M. Kiwus
AGAlina Goßling
Alina Goßling
LKLukas Koester
Lukas Koester
CBChristopher Blaum
Christopher Blaum
FBFabian J. Brunner
Fabian J. Brunner
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 September 2021 in Clinical Therapeutics
Verified
Journal Article
Closed access
CBChristopher Blaum
Christopher Blaum
FBFabian J. Brunner
Fabian J. Brunner
AGAlina Goßling
Alina Goßling
FKFriederike Kröger
Friederike Kröger
BBBenjamin Bay
Benjamin Bay
CWChristoph Waldeyer
Christoph Waldeyer

1 October 2021 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
BBB Bay
B Bay
CBC M Blaum
C M Blaum
FKF Kroeger
F Kroeger
AGA Gossling
A Gossling
Laetitia KOPPELaetitia KOPPE
Laetitia KOPPE
FBF J Brunner
F J Brunner
Background: High-sensitivity Troponin T and I (hsTnT/I) concentration is independently associated with coronary artery disease (CAD) severity and cardiovascular outcome. Here we explored whether hsTnT/I blood levels add predictive information irrespective of CAD severity and further confounders in unselected stable patients with angiographically characterized CAD. Methods: Between 2015 and 2020, 3,012 patients undergoing coronary angiography were included in the observational Hamburg INTERCATH study. In 2,209 consecutive patients Troponin levels were quantified for hsTnT (Roche Diagnostics Elecsys) and hsTnI (Abbott Diagnostics ARCHITECT STAT). Patients presenting with acute coronary syndromes and heart transplant recipients were excluded, leaving 1,841 patients for analyses. CAD severity was graded according to the Gensini score. Major adverse cardiac events (MACE) as a composite of cardiovascular death, stroke, myocardial infarction, and coronary revascularization were defined as endpoint. Kaplan-Meier analyses stratified by hsTnT/I quartiles were performed. Multivariable Cox models were computed for the association of hsTnT/I with MACE adjusting for age, gender, arterial hypertension, hyperlipoproteinemia, smoking, diabetes mellitus, body-mass index, eGFR and Gensini Score. Results: Mean age was 68.5±10.9 years (27.9% female). 81.1% were diagnosed with CAD by coronary angiography. Gensini score was 21.0±30.2. Median follow-up time was 4.42 years. hsTnT quartiles differentiated MACE across all categories (Figure 1A). For hsTnI, cardiovascular risk was differentiated between the lowest and highest quartiles as well as the 1st and 2nd quartile particularly beyond 24 months of follow-up (Figure 1B). However, MACE after 3 years was not associated with hsTnT after adjustment for classical cardiovascular risk factors and CAD severity (Figure 1C), whereas the hazard of MACE was increased in the 3rd and 4th hsTnI quartiles compared to the 1st quartile (HR 1.3, IQR 1.1–1.6 for both categories; Figure 1D). Conclusion: Increasing hsTn concentration was related to intermediate term cardiovascular outcome in unselected stable patients. Only hsTnI concentration remained as independent predictor after testing for most possible confounders, including CAD severity. This data underpins the role of hsTnI in outcome prediction. Funding Acknowledgement: Type of funding sources: None.